Professor Stricker invited by Eur. Urol to produce the editorial for PRESERVE trial.
Prof Phillip Stricker was invited by the European Journal of Urology to produce an editorial on their article in press, “Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial“.
The editorial, co-written with Matthijs Scheltema, was entitled, “Prospective Multicentre Validation of Focal Irreversible Electroporation as an Attractive Treatment Option for Localised Intermediate-risk Prostate Cancer” and endorsed the conclusion that focal irreversible electroporation (IRE) for localised intermediate-risk prostate cancer (IR-PC) is an effective and safe treatment option for all prostate segments.
Importantly, the NanoKnife System received FDA clearance for prostate tissue ablation in late 2024, following the successful completion of the PRESERVE study.